Neumora Therapeutics Inc Dossier - Source-backed chat

Neumora Therapeutics Inc

NMRANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.16

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.55Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $103.3M

Enterprise Value $99.4M

Shares Outstanding 184.3M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Neumora Therapeutics is undergoing a major strategic pivot following the complete clinical failure and discontinuation of its lead Phase 3 asset, navacaprant, in major depressive disorder (MDD) in June 2026. The company has announced a 35% workforce reduction to right-size operations and preserve capital, extending its cash runway into Q3 2027. While the pipeline still holds early-to-mid-stage assets targeting high-value indications—such as NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia, and NMRA-215 for obesity—the investment profile is now highly speculative and characterized by binary clinical risks and a compressed cash runway. A Hold rating is recommended until early clinical data validates the remaining pipeline and the company demonstrates execution under its restructured cost base.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$6.28

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case is triggered by further clinical or regulatory setbacks. NMRA-215's clinical entry is delayed beyond early 2027 due to unresolved toxicology findings, or NMRA-898's Phase 1 trial reveals safety or tolerability concerns (e.g., cholinergic side effects) typical of muscarinic agonists. Additionally, if NMRA-511 fails to show dose-dependent efficacy or exhibits safety issues in the elderly MAD cohort, the company's pipeline would be severely depleted. With a cash runway ending in Q3 2027, Neumora would face severe dilutive financing pressure or be forced to liquidate.

Base CaseCentral scenario

$2.0055%

In the base case, Neumora successfully executes its 35% workforce reduction, achieving the targeted $10 million in annualized savings and maintaining its cash runway into Q3 2027. NMRA-511 advances into a Phase 2b dose-ranging study by late 2026 after completing the healthy elderly MAD cohort. NMRA-898 reports acceptable Phase 1 safety data in H2 2026, and NMRA-215 enters the clinic around late 2026 or early 2027. However, the stock remains range-bound as the market adopts a wait-and-see approach, requiring mid-stage clinical efficacy data to drive a significant upward re-rating.

Bull CaseUpside scenario

$5.0025%

The bull case relies on the rapid clinical advancement and positive data readouts of the remaining pipeline. NMRA-511 successfully replicates its positive Phase 1b signal in a larger Phase 2b study for Alzheimer's disease agitation, establishing a clear best-in-class profile. Concurrently, NMRA-898 delivers clean Phase 1 safety and pharmacokinetic data in schizophrenia, and NMRA-215 enters the clinic on schedule by year-end 2026, demonstrating competitive weight-loss efficacy in early obesity trials. Under this scenario, Neumora's precision neuroscience platform is validated, attracting strategic partnerships or making the company an attractive acquisition target similar to historical neuroscience deals.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated remaining pipeline targeting high-value, underserved indications (Alzheimer's agitation, schizophrenia, obesity).
NMRA-511 is partially de-risked by positive Phase 1b data demonstrating a clinically meaningful effect size on the CMAI total score.
Restructuring and workforce reduction extend the cash runway into Q3 2027, providing a window to reach key early-stage data inflection points.

Key Investment Risks

High binary clinical trial risk, as highlighted by the recent complete failure of the Phase 3 navacaprant program.
Compressed cash runway (Q3 2027) leaves little margin for operational delays or trial design modifications.
Intense competition in the neuropsychiatry and obesity spaces from well-capitalized biopharmaceutical peers.

Thesis Invalidation Triggers

Failure to initiate the NMRA-511 Phase 2b study by early 2027.
Unfavorable safety or pharmacokinetic data from the NMRA-898 Phase 1 schizophrenia study in H2 2026.
Further delays in the clinical entry of NMRA-215 for obesity beyond Q1 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.